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Little is presently known about the specific routes of transmission of 
Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvi-
rus-8 (HHV-8). To investigate whether this agent might be transmitted 
vertically from mother to infant, we conducted a study on 89 KSHV 
seropositive mothers and their newborn infants. Thirteen mothers 
(14.6%) had KSHV DNA detected in their peripheral blood mononu-
clear cells (PBMC). Two of 89 samples drawn at birth from infants born 
to KSHV seropositive mothers had KSHV DNA detectable within their 
PBMC. These findings suggest that KSHV can be transmitted perina-
tally, but infrequently. Other routes of transmission such as horizon-
tal transmission remain the most likely means of KSHV transmission.
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Kaposi’s sarcoma-associated herpesvirus is a recently isolated 
gamma herpesvirus1 that has been found in all forms of Kaposi 
Sarcoma (KS),2 and is now thought to play an important role in 
the development of this tumor.3 Current knowledge about the 
routes of transmission of KSHV is limited. Serological evidence 
has suggested that there may be several routes of KSHV trans-
mission, including sexual contact, as well as nonsexual contact via 
saliva.4-7 In Africa, cross-sectional serological studies of children 
in different age groups have shown that infection with KSHV 
begins during early childhood and its frequency increases with 
age.8-12 This suggests that non-sexual modes of transmission of 
the virus may be occurring in Africa. The role of vertical trans-
mission of this virus remains poorly understood. Some studies 
have reported serological data disputing the occurrence of ver-
tical transmission of KSHV13,14 whereas others have presented 
contrasting serological data suggesting that vertical transmission 
does occur.15,16 A case report of KS in a 6-day-old child17 strongly 
suggests that KSHV may indeed be transmitted from a mother 
to her infant in utero. In our study, we present evidence showing 
that KSHV can be transmitted vertically from mother to infant.
Material and Methods
Patient recruitment
A subgroup of 89 KSHV seropositive women and their in-
fants were selected from a cohort of over 2,000 mothers partici-
pating in a prospective study at the University Teaching Hospi-
tal (UTH) in Lusaka, Zambia. In this cohort, pregnant women in 
the early stages of labor were recruited for the study at the time 
of admission to the labor ward of the University Teaching Hos-
pital (UTH), Lusaka, Zambia. Women who were in active labor 
or who had more than 5cm cervical dilation were not recruited. 
Before giving written consent to participate in the study, the 
women were informed about the purpose of the study and coun-
seled on HIV and KSHV. All women were enrolled before giving 
birth and their newborns were enrolled immediately after deliv-
ery. In case of a multiple delivery, only the first sibling was en-
rolled into the study.
Sample collection
Maternal and infant blood was collected by venipuncture into 
acid citrate dextrose tubes and processed within 6 hours of be-
ing drawn. The blood samples from the mothers were drawn be-
fore delivery and those from the infants were drawn during their 
first 24 hours of life.
Isolation of peripheral blood mononuclear cells
The blood was centrifuged at 1,800 rpm for 10 minutes and the 
plasma was collected then frozen at -20°C. The PBMC were iso-
lated from whole blood using a ficol density gradient (Nycomed 
Pharma AS, Oslo, Norway). The PBMC were then suspended in 
fresh freezing medium (70% RMPI 1640, 20% fetal bovine serum, 
10% DMSO) and stored at -80°C.
Screening for syphilis
Plasma was screened for Treponema pallidum antibodies us-
ing the rapid plasma reagin (RPR) testing kit (Arlington Scien-
tific Inc, Springville, UT). All the RPR reactive samples were 
then confirmed by Treponema pallidum hemagglutination using 
the Serodia®-TP.PA kit (Fujirebio Inc., Tokyo, Japan).
Immunofluorescence assay (IFA) for KSHV
Plasma was tested for KSHV antibodies by indirect IFA. BC-3 
cells (kindly provided by Dr. Ethel Cesarman, Weill Medical Col-
lege, Cornell University), a KSHV positive and Epstein-Barr vi-
rus (EBV) negative B-cell lymphoma cell line, were used for the 
IFA. The IFA was performed using the procedure described by 
Lennette et al.18 with minor modifications. Briefly, 5 x 105 cells/
ml were stimulated with tetra decanoyl phorbol acetate (TPA, 
20 ng/ml, Sigma, St. Louis, MO) for 72 hours in culture medium 
(90% RMPI 1640, 10% fetal calf serum, 100 U/ml penicillin G and 
100 mg/ml streptomycin). Two different lab workers tested all 
samples at 1:40 dilution. To exclude false positive results due to 
background staining, all positive sera were retested with BJAB 
cells (KSHV negative B lymphoma cell line). Only sera found 
to be negative with uninfected cells were considered positive.
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Testing for HIV-1
Plasma was screened for HIV-1 antibodies using 2 rapid 
assays, Capillus (Trinity Biotech Plc, Ireland) and Deter-
mine (Abbott Laboratories, Abbott Park, IL). The assays were 
done according to the manufacturers’ instructions. IFA was 
then used to confirm the HIV-1 result. The HIV IFA was per-
formed as described above using a chronically HIV-1 in-
fected T-cell line, HUT-78/ARV (given to us by Dr. Cecilia 
Cheng-Mayer). Uninfected HUT-78 cells were used for back-
ground control. Plasma were considered HIV-1 positive if they 
tested positive by at least one rapid test and confirmed by IFA.
Western blot analysis for antibodies to KSHV ORF65
An ORF65 bacterial clone, ORF65.2 (kindly provided by Dr. 
T. Schulz), expressing the carboxylterminal half of ORF65 with 
a 6xHis tag was used for Western blot analysis of sera. ORF65.2 
protein was expressed then purified using immobilized metal 
affinity chromatography according to the manufacturers’ pro-
cedure (Qiagen Ni-NTA Superflow, Qiagen, Chatsworth, CA). 
Western blot was performed as follows. Ten microliters of each 
test serum was blocked with 10 μl of normal E. coli bacterial 
lysate for two hours at room temperature then diluted 1:50 in 
blocking solution (20 mM Tris-HCl, pH 7.5; 500 mM NaCl; 0.1% 
Tween 20; 5% skim milk; 5% normal goat serum). The mem-
branes were incubated with the test serum for 1 hour at room 
temperature then washed with TBST (20 mM Tris-HCl, pH 7.5; 
500 mM NaCl; 0.1% Tween 20). The membrane was incubated 
with alkaline phosphatase conjugated goat anti-human IgG (Bio-
Rad, Richmond, CA) and detection was performed using ni-
troblue tetrazolium and 5-bromo-4-chloro-3indolyphosphate 
colorimetric substrate.19
Extraction of DNA from PBMC
Each cell pellet was incubated in 400 μl digestion buffer (100 
mM NaCl, 10 mM Tris-HCl, pH 8.0, 25 mM EDTA, 0.5% SDS, 0.1 
mg/ml Proteinase K) for 2 hours. Longer incubation times, up 
to 15 hours, were used for larger cell pellets. The DNA was ex-
tracted by phenol/chloroform/isoamyl alcohol (25:24:1) extrac-
tion followed by ethanol precipitation.
PCR Analysis
PCR was performed using 2 sets of primers amplifying dif-
ferent genes of the KSHV genome. The KS-1 (5′-AGCCGAAA-
GATTCCACCAT-3′, genomic locus 47586-47605) and KS-2 
(5′-TCCGTGTTGTCTACGTCCAG-3′, locus 47818-47799) prim-
ers, amplifying a 233 bp region of the ORF26 gene were used 
for screening the DNA for KSHV sequences because they were 
previously found to be most sensitive for detecting genomic 
KSHV DNA.1 An extra pair of primers KS-4 (5′-CGAATC-
CAACGGATTTGACCTC-3′, locus 47611-47633) and KS-5 
(5′-CCCATAAATGACACATTGGTGGTA-3′, locus 47785-
47761) for the ORF26 gene was also used for the nested PCR of 
the gene. Another set of primers, gBN-3 (5′-GCCACCCTGGG-
GACTGTCAT-3′, locus 8701-8720) and gBN-4 (5′-TTGGTGATG-
GCGGACTCTGTC-3′, locus 9083-9063) amplifying a 382 bp frag-
ment of the N-terminal end of the glycoprotein B gene (gBN), 
was used for screening in addition to the KS-1 and KS-2 primers. 
All the primer sets were designed from the genomic sequence 
U93872 (GenBank accession number U93872). The PCR reactions 
were carried out in a PE 2400 thermal cycler (Perkin-Elmer, Oak 
Brook, IL). Each reaction mixture (25 μl) contained 0.8 μM prim-
ers, 0.25 mM dNTP, 1.5 mM MgCl2, 20 mM Tris-HCl, pH 8.4, 50 
mM KCl and 1 U Taq polymerase (GIBCO BRL, Gaithersburg, 
MD). In every case, 300–400 ng of genomic DNA template was 
used. Fifty nanograms of BC-3 DNA were used as the positive 
control whereas 400 ng of BJAB DNA in one reaction tube and 
2 μl deionized water in a second tube were used as the negative 
controls. The cycling procedure for the KS-1, KS-2 primer pair 
was 94°C for five minutes, then 35 cycles of 94°C for 30 seconds, 
58°C for 30 seconds, 72°C for 30 seconds and one final extension 
cycle of 7 minutes at 72°C. For the KS-4 and 5 and gBN primers, 
the amplification conditions were similar except the annealing 
temperature was at 53°C and 62°C, respectively.
Southern blot analysis
DNA was transferred onto a Zeta-Probe® nylon membrane 
(Bio-Rad Laboratories, Hercules, CA) by vacuum transfer for 
90 minutes and then cross-linked by ultra-violet irradiation. 
Digoxigenin labeled PCR products from ORF26 and glycopro-
tein B were then used as probes, following a standard protocol 
for hybridization and detection using nitroblue tetrazolium and 
5-bromo-4-chloro-3-indolyphosphate colorimetric substrate.19
Cloning and sequencing of PCR products
The amplified product of the ORF26 nested reaction was 
cloned into pGEM-T vector (Promega, Madison, WI) and the 
cloned fragment was sequenced using ABI PRISM Big-dye ter-
minator sequencing kit on an ABI 373S DNA sequencer (Applied 
Biosystems; San Jose, CA).
Results
Medical history and clinical examination of the study participants
To document the occurrence of vertical transmission of KSHV 
from seropositive mothers to their newborns, 89 women and 
their infants in which DNA was available, were selected from the 
group of HHV-8 seropositive women in an ongoing cohort study 
in Zambia. The medical histories of the mothers are summarized 
in Table I. Seven mothers had a positive history of tuberculosis. 
One of the 89 women had a history of gonorrhea. Thirteen moth-
ers had histories of ulcerative genital diseases. Clinical exami-
nation at the time of recruitment documented that ten mothers 
had genital warts. Five mothers had non-genital skin ulcers. Two 
women had Kaposi Sarcoma-like skin lesions but could not be 
confirmed upon histological examination.
Serological analysis for KSHV antibodies in the mothers and their infants
Of the 89 mothers testing positive for KSHV by IFA, 72 (81%) 
were also seropositive by ORF65 Western blot (Table II). Fifty-
one women (57%) had a KSHV antibody titer greater than 1:40 
(ranging from 1:80 to 1:1,280). With regards to HIV-1, 32 (36%) 
of the 89 women in the cohort were HIV-1 seropositive with 8 
of them (9%) also positive for syphilis (Table I). The infants born 
to these 89 women were also characterized. The male:female ra-
tio of the infants was 1:1. The mean birth weight was 2,852 g 
(range 1,300–4,100 g). All the infants were born healthy and were 
breast fed within the first 24 hours of their life. Most of the in-
fants (74/89, 83.1%) were found to have passively acquired anti-
KSHV antibodies at birth by IFA (Table II). The acquisition of 
maternal antibodies, however, did not correlate with high ma-
ternal antibody titers (data not shown).
PCR analysis of infant PBMC DNA for KSHV sequences
To determine if any of the infants born to these 89 KSHV sero-
positive women had acquired KSHV infection from their moth-
ers, PCR was first performed on the infant PBMC DNA obtained
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at birth using the ORF26 primers. Of the 89 infant DNA samples 
analyzed, KSHV DNA sequences were detected in two infants 
after Southern blot analysis using a probe specific for the ORF26 
gene. To confirm that KSHV DNA was indeed present in the in-
fant PBMC, a second PCR assay was performed using primers 
specific for the N-terminus of glycoprotein B. The same two in-
fants were also positive using these primers.
PCR analysis of maternal PBMC DNA for KSHV sequences
The PBMC DNA of the 89 women was also analyzed for the 
presence of KSHV DNA by PCR using primers specific for 
ORF26. KSHV DNA was detected in 13 (14.6%) mothers (Ta-
ble II). The PCR signal was quite weak and only detectable after 
Southern blotting. Nine of the 13 KSHV DNA positive mothers 
were HIV-1 seropositive (p < 0.001) indicating a possible corre-
lation between HIV-1 infection and the presence of KSHV DNA 
in this group of women. The number of specimens analyzed was 
extremely small, however, and needs to be substantiated. Fur-
thermore, we observed that five of the 13 KSHV DNA positive 
mothers had a history of genital ulcers. The significance of such 
an observation or whether there is a correlation between hav-
ing KSHV DNA and a history of genital ulcers is not clear at this 
point. The mothers of the two KSHV DNA positive infants were 
also positive for KSHV DNA by PCR, but only one of the two 
mothers was positive with both ORF26 and gBN primers. Both of 
these mothers had KSHV antibody titers of 1:160, were HIV-1 se-
ronegative and did not have any other conditions that may have 
been risk factors for vertical transmission. The two mothers that 
had unconfirmed KS-like lesions at the time of recruitment were 
not found to be PCR positive for KSHV DNA in their PBMC.
KSHV DNA sequence analysis
The amplified ORF26 gene product from one of the infants was 
cloned and sequenced. The cloned sequence is closely related to 
recently published Zambian KSHV and other African sequences 
with a conserved C at position 47738 of the ORF.17,18 This point 
mutation is conserved amongst all Zambian KSHV ORF26 genes 
sequenced so far and is distinct from BCBL KSHV sequences.20 The 
infant sequence also had a unique point mutation (C to A) at posi-
tion 47702 of the ORF26 sequence. This mutation was distinct from 
the other known Zambian KSHV sequences (Figure 1). Several 
attempts were made to clone the KSHV PCR product from the 
mother of the infant in which we had KSHV sequence informa-
tion on. The maternal signal has consistently been weak and 
only detectable by Southern blot. Subsequent cloning and anal-
ysis of the KSHV sequence from this patient was unsuccessful.
Discussion
Since the discovery of KSHV, the question of whether this agent 
can be vertically transmitted has been intensely debated. Previ-
ous reports have presented serologic evidence disputing the pos-
sibility of vertical transmission of this virus.13,14 In these studies, 
the clearance of maternal KSHV antibodies among infants fol-
lowed longitudinally was demonstrated and KSHV DNA was 
not detected in any of the infants tested. Plancoulaine et al.22 re-
cently demonstrated in a French Guyana population of African 
descent that KSHV transmission mainly occurs postnatally from 
mother to child and from sibling to sibling. The low seropreva-
lence of KSHV among children less than 5 was cited as evidence 
against vertical transmission being a major route of transmis-
sion. It has also previously been documented in Africa that pri-
mary infection with KSHV can occur during childhood.8-12 Ka-
solo et al.20 reported the finding of KSHV sequences in PBMC of 
infants with febrile illnesses. The reported cases of KS in infants 
less than 6 months of age,17,23 however, suggest the potential of 
vertical transmission of KSHV. Our hypothesis that KSHV might 
be transmittable from mother to infant perinatally was based 
upon two previous observations: first that KS has become one of 
the most common tumors among infants and children in Zam-
bia and second, that KS is closely associated with KSHV infec-
tion. We have now identified two neonates who have tested pos-
itive for KSHV DNA at birth. This finding in these two infants 
provides direct evidence of vertical transmission of KSHV. Inter-
estingly, both infants were born to HIV-1 negative mothers. We 
think that this is a chance finding. One would expect that HIV-1 
positive mothers would be more likely to vertically transmit 
KSHV to their babies because of higher viral copy numbers as a 
result of their immunosuppression. We do not believe that these 
results were due to contamination because KSHV DNA was de-
tected in only two of the 89 infants that we tested. The fact that 
PCR was done on the infants before DNA extraction and PCR on 
the mothers PBMC DNA supports the claim that it is not a con-
tamination from maternal sequences. Separate laboratories were 
used for the extraction of DNA and PCR and the results were 
confirmed by different researchers. Also, these same two infants 
were positive with two different sets of non-nested PCR primers. 
Furthermore, sequence analysis of the ORF26 gene from one of the 
infants revealed that it is closely related to previously published 
Zambian sequences of the same gene. Therefore contamination 
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from maternal sequences or the laboratory BCBL strain is un-
likely. The cloned portion of the ORF26 sequence, however, is 
known to be relatively conserved and in our infant sequence, we 
detected only two nucleotide changes with one of the changes 
being conserved amongst Zambian KSHV isolates. We were 
unable to clone other KSHV genes that show more variability 
such as the ORF K1, or KSHV sequences from the mothers of the 
two PCR-positive infants due to weak signals and insufficient 
DNA. Although KSHV viral DNA in the PBMC of two infants 
has been detected, it is difficult to determine whether infection 
occurred in utero or intrapartum. Intrapartum or postnatal expo-
sure as a result of breast feeding is unlikely because KSHV DNA 
would not have been detected in the immediate postnatal period.
KSHV DNA has consistently been detected in KS tissues and 
the viral copy numbers in these tissues are usually high.24 Other 
tissues and body fluids in which KSHV DNA has been detected 
include saliva, semen, skin, cervical secretions and PBMC.24-26 
KSHV DNA is more easily detected in the bodily fluids of in-
dividuals with KS than in those without KS.24 This may be due 
to lower copy numbers of KSHV DNA in individuals without 
KS. In our study, we detected KSHV DNA in the PBMC of ap-
proximately 15% of the mothers. The KSHV copy numbers in the 
PBMC DNA seem to be very low as we were only able to detect 
the viral DNA by Southern blot analysis and not by direct gel ex-
amination of PCR-amplified products. In our hand, the limits of 
detection of KSHV by the ORF26 and glycoprotein B PCR were 
3 and 20 copies of viral DNA respectively. An increase in the 
detection of KSHV DNA in HIV-1 positive mothers (9/13) com-
pared to the HIV-1 negative mothers (4/13) was found to be sta-
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